The Dementia Trials Accelerator (DTA): a UK dementia trials-ready cohort

Résumé fourni par la source

ABSTRACT The Dementia Trials Accelerator (DTA) is a UK-wide programme designed to improve the feasibility, efficiency, and inclusiveness of recruitment into clinical trials of dementia and related brain-health conditions. Dementia trials are frequently constrained by the difficulty and cost of identifying eligible participants, which often requires cognitive assessments and measurement of blood-based biomarkers. The DTA addresses these barriers with two linked services. First, the DTA provides a federated platform to improve findability of potential participants across existing UK-based cohorts with consent to recontact. A single point of contact across multiple cohorts would allow increased efficiency of search for participants for studies. Second, the DTA provides a community-centred pre-screening service with information relevant to trial eligibility and a linked plasma and DNA tissue bank, with participants’ consent for recontact. Participants aged 65-75 years are approached via existing cohorts and registries. Consenting participants complete an online questionnaire and digital cognitive assessment, attend an in-person assessment for physical measures and face-to-face cognitive testing, and provide venous blood samples which are processed to plasma and whole blood for long-term storage and biomarker measurement. The initial programme target is to recruit at least 10,000 participants into the DTA pre-screening service. The DTA is designed to support approved academic and industry studies by enabling the DTA team to approach eligible participants for specific studies, without transferring identifiable information without consent. In parallel with its immediate trial-readiness purpose, the DTA is positioned to interoperate with emerging national approaches to biomarker-led recruitment by generating high-quality, recontactable cohorts with standardised cognitive characterisation and scalable biosampling suitable for blood-based biomarkers.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.